Viewing Study NCT05030506

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 1:16 PM
Ignite Modification Date: 2026-06-08 @ 5:52 AM
Study NCT ID: NCT05030506
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-18
First Post: 2021-08-30
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
Sponsor: Merck Sharp & Dohme LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Renal Cell Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Belzutifan View
None Pembrolizumab View
None Programmed Cell Death-1 (PD1) View
None Hypoxia inducible factor 2 alpha (HIF-2 alpha) View
None Hypoxia inducible factor 2α (HIF-2α) View
None Renal Cell Carcinoma (RCC) View
None Kidney Cancer View
None MK-6482 View
None MK6482 View
None PT-2977 View
None PT2977 View
None MK-3475 KEYTRUDA® View
None MK-7902 View
None E7080 View
None LENVIMA® View